This year's HIMSS conference featured many news announcements — from advanced partnerships to product launches to new research. In this list, MedCity News compiled short summaries for six of the conference's most notable announcements.
The mHUB MedTech Accelerator is a six-month program, based in Chicago, run in partnership with Baxter and Edward-Elmhurst Health Venture Capital. The application deadline is Monday, August 23.
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.
Last month, medical device company Ivenix received clearance for a new smart infusion pump meant to address the safety issues endemic to the industry with more streamlined and intuitive technology.
Baxter International, a medical device company, and Matter, a health technology incubator, will work together to improve healthcare quality and value.
During a panel at MedCity INVEST, four experts addressed what VCs and potential acquirers are looking for in emerging companies.
The goal is to develop best practices for healthcare organizations and device manufacturers.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Rare disease specialist Shire has made a $30B offer to acquire biopharma company Baxalta, and patient readmission costs have added up to $420M resulting in penalties against hospitals.
If there’s any truth to the notion that corporate VC-backed companies have a higher rate of overall success than those without corporate VC funding, here’s a company we should be keeping an eye on. Naurex Inc., a young pharmaceutical company focused on psychiatry and neurology, rounded up $38 million from lead investor Baxter Ventures and […]
Gliknik, which is testing cancer drugs and has developed a compound that it hopes will mimic the effects of IVIG, has just raised $4.9 million, some of it coming from Baxter Ventures.
Researchers have identified a potential threat that could result in hospital-acquired infections — bacterial contamination of automated pharmacy robots that mix intravenous medications. In a paper published in Infection Control and Hospital Epidemiology, researchers said that their report was the first to their knowledge that detailed a pharmacy robot being contaminated with bacteria and the […]
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
If you’re looking to do clinical trials for Lyme disease-related treatments, new research funded by the Centers for Disease Control and Prevention shows that New Jersey and Wisconsin are hot spots for the disease. Durland Fish, a professor of Epidemiology at Yale School of Public Health, said the researchers had found of a search of […]
Minnesota’s Synovis Life Technologies Inc. is being acquired by Baxter International Inc. in a $325 million deal, the companies announced today. Synovis’ board unanimously approved the buy at $28 per share. Pending shareholder approval, the deal is expected to close in the first quarter of 2012. The maker of biological and mechanical products for surgeries […]
Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCitynews.com. Now here’s the best of what YOU had to say: Baxter Ventures will invest $200 million in early-stage companies. Baxter International put aside $200 million in equity to invest in early-stage […]
Baxter International Inc. (NYSE: BAX) put aside $200 million in equity to invest in early-stage companies that “complement” its portfolio. The newly established ” Baxter Ventures will invest globally and focus on innovative technologies with sustainable long-term growth” under the watch of the Deerfield, Ill.-based company’s chief scientific officer Norbert Riedel, according to a press release. […]
Baxter International Inc. (NYSE:BAX) is planning to offload its U.S.-based generic injectables business to British drug firm Hikma Pharmaceuticals PLC (LSE:HIK). The deal is worth about $112 million to the Deerfield, Illinois-based company, according to a statement. The agreement is comprised of Hikma acquisition of Baxter’s injectable products in vials and ampules, which are marketed […]